Company Overview and News
KeyCorp’s (KEY - Free Report) first-quarter 2018 earnings of 38 cents per share came in line with the Zacks Consensus Estimate. Also, this compared favorably with adjusted earnings of 32 cents per share recorded in the prior-year quarter. Improvement in both net interest income and fee income drove results. Further, a decline in provision for credit losses and improving loans acted as tailwinds. However, an increase in expenses was on the downside.
Have you been eager to see how KeyCorp (KEY - Free Report) performed in Q1 in comparison with the market expectations? Let’s quickly scan through the key facts from this Cleveland-based bank-oriented financial services company’s earnings release this morning: In Line Earnings KeyCorp came out with earnings per share of 38 cents in line with the Zacks Consensus Estimate. Rise in revenue supported the results.
Earnings season for banks has already begun and the results released so far by the big names reflect a decent performance. The results till now indicate higher revenues supported by improved loan balances, hike in interest rates and rebound in trading activities. However, lower mortgage income and dismal investment banking performance adversely impacted fee income to some extent. On the cost front, the chance of a significant rise in expenses is low, though a marginal increase in expenses is expected to occur owing to efforts to digitize operations and investment in franchise.
KeyCorp (KEY - Free Report) , slated to announce first-quarter 2018 results on Apr 19, is expected to show improvement in net interest income (NII), driven by higher interest rates. Per the Fed’s latest data, commercial and industrial loans recorded solid growth year over year, even though the quarter witnessed a modest improvement in lending activities. The Zacks Consensus Estimate for average total loans of $87.
This month’s article marks the thirty-seventh installment in my on-going series outlining my efforts to achieve dividend growth success. The portfolio is nicknamed the MnM portfolio, which is a moniker for “Minne(sota) ‘n Monthly.”
Over the last four trading days, performance of banking stocks has been encouraging. Easing U.S.-China trade war tension has provided some respite to investors, infusing overall positivity in the market. Mortgage rates declined this week, hitting 4.4%, along with bond yields, on fears of a trade war. Despite this, investors are apprehensive about parking funds in the housing market, thanks to the volatility in the financial world.
The other day I was asked by one of my readers: "Do you know how much new money you will have to contribute to the BBP each year (month) to reach your dividend goal?" My immediate thought was "Yes, of course - if I can maintain a yield of 6.6% I will need approximately $250,000." Therefore if I have approximately $20,000 invested now and with an approximate 15 year horizon, that leaves me investing $15,333 a year over the next 15 years, or $1277.
Continuing with the aim of focusing on core operations, KeyCorp (KEY - Free Report) is set to sell Key Insurance & Benefits Services, Inc. Notably, the unit was acquired as part of the First Niagara Financial Group merger in 2016. Last week, KeyBank, the banking subsidiary of KeyCorp signed a deal to vend the unit to USI Insurance Services ("USI"), the New York insurance broker. The deal, awaiting certain regulatory approvals, is anticipated to close in second-quarter 2018.
Congress is scrambling to avoid its third government shutdown of the year as lawmakers slog through negotiations ahead of next week's deadline. Republicans had hoped to buy themselves some extra time by having the House vote on a mammoth funding bill this week. That would have helped the Senate avoid an hours-long shutdown like the one forced last month by Sen. Rand Paul (R-Ky.). But that timeline appears to be slipping amid a standoff on controversial policy riders.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...
as of ET